Microbot Medical (MBOT) risk factors

41 risks, 4 new, 6 dropped, 10 reworded since the prior year. Microbot transitioned from a research-stage company to commercializing its sole product, the LIBERTY Endovascular Robotic Surgical System.

43 risks. Microbot operates as an early-stage medical device company facing continuous operating losses and dependence on the LIBERTY system. Operations and key personnel are heavily concentrated in Israel, creating regional geopolitical and military vulnerabilities. Intellectual property protection, regulatory approvals from the FDA and foreign bodies, and third-party manufacturing partnerships are critical to future commercialization.